Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
IGC Pharma ( (IGC) ) has issued an update.
IGC Pharma, Inc. announced an amendment to its Articles of Incorporation to increase its authorized common stock from 150 million to 600 million shares, effective December 12, 2025. This decision, approved by stockholders on October 10, 2025, aims to enhance the company’s capital structure and potentially impact its market operations by expanding its capacity to issue more shares.
The most recent analyst rating on (IGC) stock is a Hold with a $0.34 price target. To see the full list of analyst forecasts on IGC Pharma stock, see the IGC Stock Forecast page.
Spark’s Take on IGC Stock
According to Spark, TipRanks’ AI Analyst, IGC is a Neutral.
IGC Pharma’s overall stock score reflects significant financial challenges, particularly in profitability and revenue growth. The technical analysis shows mixed signals with no strong momentum. Valuation remains unattractive due to negative earnings. However, the recent corporate event involving asset sales is a positive step towards improving financial stability.
To see Spark’s full report on IGC stock, click here.
More about IGC Pharma
Average Trading Volume: 716,100
Technical Sentiment Signal: Strong Sell
Current Market Cap: $32.29M
For a thorough assessment of IGC stock, go to TipRanks’ Stock Analysis page.